Why antibacterial minor groove binders are a good thing

Colin J. Suckling, Abedawn Khalaf, Fraser J. Scott, Nicholas Tucker, Leena Niemenen, Kimon Lemonidis, Iain S. Hunter

Research output: Contribution to conferencePaper

Abstract

The challenge of antimicrobial resistance is well understood and extensive research is underway worldwide to find effective, new antibacterial agents that will be less susceptible to the emergence of resistance than those of previous generations. The challenge of combining potency with resilience is unlikely to be met using the standard medicinal chemistry paradigm of single drug, single target, single effect. Our approach using specially designed minor groove binders for DNA (Strathclyde MGBs), whilst formally attacking a single molecular target, in practice disrupts many biological processes such that the emergence of resistance can be expected to be low. The first example of this approach to reach the clinic, MGB-BP-3, is highly effective against Gram positive bacteria and has been successfully taken through a Phase 1 clinical trial for the treatment of Clostridium difficile infections by our development partner, MGB Biopharma. Mechanism of action studies with S. aureus as the target organism have provided evidence consistent with the expectation. RNAseq experiments have shown that there are substantial changes in gene expression, some upregulated and others downregulated, such that the bacterium faces multiple metabolic challenges to its survival. In particular processes associated with cell wall integrity and energy production are affected, the latter being consistent with the steep dose response kill curve observed with this type of drug. Moreover attempts to generate resistant strains have failed. Taken together, these properties identify Strathclyde minor groove binders as significant new compounds in the fight against antibacterial resistance.

Conference

Conference3rd International Electronic Conference on Medicinal Chemistry
Period1/11/1730/11/17
Internet address

Fingerprint

Binders
Bacteria
Clostridium Infections
Biological Phenomena
Clostridium
Clinical Trials, Phase I
Clostridium difficile
Pharmaceutical Chemistry
Gram-Positive Bacteria
Gene expression
Pharmaceutical Preparations
Cell Wall
Down-Regulation
Cells
Anti-Bacterial Agents
Gene Expression
DNA
Research
Experiments

Keywords

  • antibacterial
  • minor groove binders
  • antimicrobial resistance
  • DNA

Cite this

Suckling, C. J., Khalaf, A., Scott, F. J., Tucker, N., Niemenen, L., Lemonidis, K., & Hunter, I. S. (2017). Why antibacterial minor groove binders are a good thing. Paper presented at 3rd International Electronic Conference on Medicinal Chemistry, . https://doi.org/10.3390/ecmc-3-04651
Suckling, Colin J. ; Khalaf, Abedawn ; Scott, Fraser J. ; Tucker, Nicholas ; Niemenen, Leena ; Lemonidis, Kimon ; Hunter, Iain S. / Why antibacterial minor groove binders are a good thing. Paper presented at 3rd International Electronic Conference on Medicinal Chemistry, .21 p.
@conference{eea038b0f0d746039c38d63abc27f038,
title = "Why antibacterial minor groove binders are a good thing",
abstract = "The challenge of antimicrobial resistance is well understood and extensive research is underway worldwide to find effective, new antibacterial agents that will be less susceptible to the emergence of resistance than those of previous generations. The challenge of combining potency with resilience is unlikely to be met using the standard medicinal chemistry paradigm of single drug, single target, single effect. Our approach using specially designed minor groove binders for DNA (Strathclyde MGBs), whilst formally attacking a single molecular target, in practice disrupts many biological processes such that the emergence of resistance can be expected to be low. The first example of this approach to reach the clinic, MGB-BP-3, is highly effective against Gram positive bacteria and has been successfully taken through a Phase 1 clinical trial for the treatment of Clostridium difficile infections by our development partner, MGB Biopharma. Mechanism of action studies with S. aureus as the target organism have provided evidence consistent with the expectation. RNAseq experiments have shown that there are substantial changes in gene expression, some upregulated and others downregulated, such that the bacterium faces multiple metabolic challenges to its survival. In particular processes associated with cell wall integrity and energy production are affected, the latter being consistent with the steep dose response kill curve observed with this type of drug. Moreover attempts to generate resistant strains have failed. Taken together, these properties identify Strathclyde minor groove binders as significant new compounds in the fight against antibacterial resistance.",
keywords = "antibacterial, minor groove binders, antimicrobial resistance, DNA",
author = "Suckling, {Colin J.} and Abedawn Khalaf and Scott, {Fraser J.} and Nicholas Tucker and Leena Niemenen and Kimon Lemonidis and Hunter, {Iain S.}",
year = "2017",
month = "11",
day = "1",
doi = "10.3390/ecmc-3-04651",
language = "English",
note = "3rd International Electronic Conference on Medicinal Chemistry ; Conference date: 01-11-2017 Through 30-11-2017",
url = "https://sciforum.net/conference/ecmc-3",

}

Suckling, CJ, Khalaf, A, Scott, FJ, Tucker, N, Niemenen, L, Lemonidis, K & Hunter, IS 2017, 'Why antibacterial minor groove binders are a good thing' Paper presented at 3rd International Electronic Conference on Medicinal Chemistry, 1/11/17 - 30/11/17, . https://doi.org/10.3390/ecmc-3-04651

Why antibacterial minor groove binders are a good thing. / Suckling, Colin J.; Khalaf, Abedawn; Scott, Fraser J.; Tucker, Nicholas; Niemenen, Leena; Lemonidis, Kimon; Hunter, Iain S.

2017. Paper presented at 3rd International Electronic Conference on Medicinal Chemistry, .

Research output: Contribution to conferencePaper

TY - CONF

T1 - Why antibacterial minor groove binders are a good thing

AU - Suckling, Colin J.

AU - Khalaf, Abedawn

AU - Scott, Fraser J.

AU - Tucker, Nicholas

AU - Niemenen, Leena

AU - Lemonidis, Kimon

AU - Hunter, Iain S.

PY - 2017/11/1

Y1 - 2017/11/1

N2 - The challenge of antimicrobial resistance is well understood and extensive research is underway worldwide to find effective, new antibacterial agents that will be less susceptible to the emergence of resistance than those of previous generations. The challenge of combining potency with resilience is unlikely to be met using the standard medicinal chemistry paradigm of single drug, single target, single effect. Our approach using specially designed minor groove binders for DNA (Strathclyde MGBs), whilst formally attacking a single molecular target, in practice disrupts many biological processes such that the emergence of resistance can be expected to be low. The first example of this approach to reach the clinic, MGB-BP-3, is highly effective against Gram positive bacteria and has been successfully taken through a Phase 1 clinical trial for the treatment of Clostridium difficile infections by our development partner, MGB Biopharma. Mechanism of action studies with S. aureus as the target organism have provided evidence consistent with the expectation. RNAseq experiments have shown that there are substantial changes in gene expression, some upregulated and others downregulated, such that the bacterium faces multiple metabolic challenges to its survival. In particular processes associated with cell wall integrity and energy production are affected, the latter being consistent with the steep dose response kill curve observed with this type of drug. Moreover attempts to generate resistant strains have failed. Taken together, these properties identify Strathclyde minor groove binders as significant new compounds in the fight against antibacterial resistance.

AB - The challenge of antimicrobial resistance is well understood and extensive research is underway worldwide to find effective, new antibacterial agents that will be less susceptible to the emergence of resistance than those of previous generations. The challenge of combining potency with resilience is unlikely to be met using the standard medicinal chemistry paradigm of single drug, single target, single effect. Our approach using specially designed minor groove binders for DNA (Strathclyde MGBs), whilst formally attacking a single molecular target, in practice disrupts many biological processes such that the emergence of resistance can be expected to be low. The first example of this approach to reach the clinic, MGB-BP-3, is highly effective against Gram positive bacteria and has been successfully taken through a Phase 1 clinical trial for the treatment of Clostridium difficile infections by our development partner, MGB Biopharma. Mechanism of action studies with S. aureus as the target organism have provided evidence consistent with the expectation. RNAseq experiments have shown that there are substantial changes in gene expression, some upregulated and others downregulated, such that the bacterium faces multiple metabolic challenges to its survival. In particular processes associated with cell wall integrity and energy production are affected, the latter being consistent with the steep dose response kill curve observed with this type of drug. Moreover attempts to generate resistant strains have failed. Taken together, these properties identify Strathclyde minor groove binders as significant new compounds in the fight against antibacterial resistance.

KW - antibacterial

KW - minor groove binders

KW - antimicrobial resistance

KW - DNA

U2 - 10.3390/ecmc-3-04651

DO - 10.3390/ecmc-3-04651

M3 - Paper

ER -

Suckling CJ, Khalaf A, Scott FJ, Tucker N, Niemenen L, Lemonidis K et al. Why antibacterial minor groove binders are a good thing. 2017. Paper presented at 3rd International Electronic Conference on Medicinal Chemistry, . https://doi.org/10.3390/ecmc-3-04651